Skip to Content
MilliporeSigma
All Photos(1)

Documents

AB9604

Sigma-Aldrich

Anti-Semaphorin 3A Antibody, central region

Chemicon®, from rabbit

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human, rat

manufacturer/tradename

Chemicon®

technique(s)

western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... SEMA3A(10371)

Specificity

It is expected that the antibody will also react with mouse.
Semaphorin 3A. The immunogen sequence has low homology with other semaphorin family members.

Immunogen

Synthetic peptide from the central region of human semaphorin 3A.

Application

Anti-Semaphorin 3A Antibody, central region detects level of Semaphorin 3A & has been published & validated for use in WB.
Western blot: 1:1,000 on neonatal rat brain and recombinant human Semaphorin 3A/Fc chimera (95/125 kDa). The antibody reacts with the ~95 kDa protein. The suggested antibody diluent is PBS containing 5% non-fat milk and 0.04% Tween 20.

Optimal working dilutions must be determined by the end user.

Physical form

Liquid in PBS containing 50% glycerol, 1 mg/mL BSA and 0.05% sodium azide.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 2


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Haynes Shek Hei Yuan et al.
Oncotarget, 9(32), 22618-22630 (2018-06-02)
One hallmark of cancer is its ability to recruit a vascular supply to support rapid growth. Suppression of angiogenesis holds potential as a second-line or adjuvant therapy to stunt cancer growth, progression, metastasis, and post-resection regeneration. To begin to test
Transmembrane proteoglycans syndecan-2, 4, receptor candidates for the impact of HGF and FGF2 on semaphorin 3A expression in early-differentiated myoblasts.
Do, MK; Shimizu, N; Suzuki, T; Ohtsubo, H; Mizunoya, W; Nakamura, M; Sawano, S; Furuse et al.
Physiological Reports null

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service